Chendil Damodaran on Prostate Cancer-Reducing Therapy

1. Chendil Damodaran on Prostate
Cancer-Reducing Therapy

2. Chendil Damodaran is a cancer research veteran and
assistant professor at the Paul L. Foster School of
Medicine, which is located at Texas Tech University
Health Sciences Center. One of Chendil Damodaran's
most recent studies, regarding an intervention that could
possibly treat and prevent prostate cancer, was in the
September 2010 issue of the journal Molecular Cancer
Therapeutics. Chendil Damodaran and his associates
performed the research at the Department of Clinical
Sciences, College of Health Sciences, at the University
of Kentucky.

3. The research centers around the epidermal growth
factor receptor, which is particularly relevant in its role in
prostate cancer. According to the research, inhibiting
activity surrounding the epidermal growth factor receptor
could suppress growth of prostate cancer and its
subsequent progression. One drug that activates this
inhibition is called psoralidin, which was shown to
modulate epidermal growth factor receptor-mediated
events. Not only did psolaridin inhibit epidermal growth
factor receptor activity, but the drug therapy also
triggered stress-mediated protein kinases, which are
known to kill cancer cells.